Finance

Lists
Q3 2026 earnings • in 3 days
See details
HUM:NYSE
Humana Inc
$410.41
-0.99%
(-4.09) 1D
$410.41
0.00% (0.00)
After hours
Closed: Nov 2, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for HUM...
Open
$420.64
High
$420.64
Low
$399.35
Mkt. cap
49.28B
Avg. vol.
1.49M
Volume
917.99K
Dividend
0.86%
Quarterly dividend
$0.88
Ex-dividend date
Oct 30, 2026
P/E ratio
38.87
52-wk high
$456.50
52-wk low
$163.11
EPS
$10.56
Beta
0.74
Shares outstanding
120.08M
No. of employees
67K
Open
$420.64
High
$420.64
Low
$399.35
Mkt. cap
49.28B
Avg. vol.
1.49M
Volume
917.99K
Dividend
0.86%
Quarterly dividend
$0.88
Ex-dividend date
Oct 30, 2026
P/E ratio
38.87
52-wk high
$456.50
52-wk low
$163.11
EPS
$10.56
Beta
0.74
Shares outstanding
120.08M
No. of employees
67K
News stories
From web sources and news partners
Profile
Humana Inc. is an American for-profit health insurance company based in Louisville, Kentucky. In 2024, the company ranked 92 on the Fortune 500 list. It is the fourth largest health insurance provider in the U.S. Wikipedia
About Humana Inc
CEOJim Rechtin
Employees67.1K
Founded1961
HeadquartersLouisville, Kentucky, United States
SectorHealth care provider
Websitehumana.com
Analyst ratings
Based on 17 analysts giving stock ratings to HUM in the past 3 months
Buy
Buy
12
Hold
5
Sell
0
12-month forecast
Based on 17 Wall Street analysts offering 12 month price targets for HUM in the last 3 months.
Highest
Current $410.41
$596.00 (+45.22%)
Average
$473.38 (+15.34%)
Lowest
$370.00 (-9.85%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Cassorla
Guggenheim
Buy
Maintained
$471.00
+14.8%
10/20/2026
Andrew Mok CFA
Barclays
Buy
Maintained
$582.00
+41.8%
10/14/2026
Elizabeth Anderson CFA
Evercore ISI
Buy
Maintained
$480.00
+17%
10/13/2026
Ann Hynes
Mizuho Securities
Buy
Maintained
$495.00
+20.6%
10/13/2026
A.J. Rice
UBS
Hold
Reiterated
$495.00
+20.6%
10/12/2026
David S Macdonald
Truist Financial
Hold
Maintained
$475.00
+15.7%
10/12/2026
Parker Snure
Raymond James
Buy
Upgraded
$520.00
+26.7%
10/12/2026
John Ransom
Raymond James
Buy
Upgraded
$520.00
+26.7%
10/12/2026
Michael Wiederhorn
Oppenheimer
Buy
Maintained
$475.00
+15.7%
10/09/2026
Michael Ha
Robert W. Baird
Buy
Upgraded
$596.00
+45.2%
10/09/2026
Sarah James
Cantor Fitzgerald
Buy
Upgraded
$460.00
+12.1%
10/07/2026
Ben Hendrix
RBC Capital
Hold
Maintained
$415.00
+1.1%
10/07/2026
Lance Wilkes
Bernstein
Buy
Maintained
$425.00
+3.6%
10/05/2026
David Windley
Jefferies
Buy
Maintained
$420.00
+2.3%
09/30/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
$502.00
+22.3%
09/15/2026
Kevin Fischbeck
Bank of America Securities
Buy
Reiterated
-
-
09/08/2026
Lisa Gill
J.P. Morgan
Hold
Reiterated
$393.00
-4.2%
08/10/2026
Erin Wright
Morgan Stanley
Hold
Upgraded
$370.00
-9.8%
08/05/2026
Ryan Langston
TD Cowen
Hold
Reiterated
$370.00
-9.8%
07/31/2026
Jessica Tassan
Piper Sandler
Buy
Upgraded
$463.00
+12.8%
07/30/2026
George Hill
Deutsche Bank
Buy
Maintained
$436.00
+6.2%
07/30/2026
Scott Fidel
Goldman Sachs
Sell
Maintained
$280.00
-31.8%
07/30/2026
Whit Mayo
Leerink Partners
Buy
Upgraded
$513.00
+25%
07/30/2026
Matthew Gillmor CFA
KeyBanc
Hold
Maintained
-
-
07/30/2026
Courtney Breen
Bernstein
Buy
Maintained
$288.00
-29.8%
05/27/2026
Kevin Caliendo
UBS
Hold
Maintained
$262.00
-36.2%
04/30/2026
Next call in 3 days
Fri, Nov 6, 8:00 AM
Fiscal period
Q3 2026
- / -$1.00
Revenue / Est. (USD)
- / 40.89B
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
32.65B
32.52B
39.65B
40.87B
Cost of goods sold
27.99B
28.72B
33.71B
35.37B
Cost of revenue
27.99B
28.72B
33.71B
35.37B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.82B
4.21B
3.93B
3.92B
Operating expense
3.99B
4.38B
4.09B
4.08B
Total operating expenses
31.98B
33.10B
37.80B
39.45B
Operating income
667.00M
-583.00M
1.85B
1.42B
Other non operating income
-35.00M
-53.00M
34.00M
-211.00M
EBT including unusual items
108.00M
-1.02B
1.58B
931.00M
EBT excluding unusual items
438.00M
-796.00M
1.68B
987.00M
Income tax expense
-86.00M
-249.00M
395.00M
238.00M
Effective tax rate
-79.63%
24.29%
25.02%
25.56%
Other operating expenses
-
-
-
-
Net income
195.00M
-796.00M
1.19B
694.00M
Net profit margin
0.60%
-2.45%
2.99%
1.70%
Earnings per share
3.24
-3.96
10.31
7.61
Interest and investment income
-
-
-
-
Interest expense
-168.00M
-146.00M
-193.00M
-197.00M
Net interest expenses
-168.00M
-146.00M
-193.00M
-197.00M
Depreciation and amortization charges
173.00M
164.00M
163.00M
159.00M
EBITDA
871.00M
-389.00M
2.05B
1.60B
Gain or loss from assets sale
63.00M
4.00M
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps